Allogeneic Stem Cell Transplant: What It Is and When Doctors Recommend It

Research-informed explainer — last updated April 12, 2026

Allogeneic stem cell transplant (allo-SCT) remains the only treatment capable of curing certain blood cancers, including AML, MDS, CLL, and some lymphomas — but it carries substantial risks including graft-versus-host disease, infection, and treatment-related mortality, and is appropriate only for selected patients. The critical decisions involve choosing the right donor, the right conditioning intensity, and the right disease stage at which to proceed.

This article draws on research from five transplant specialists whose published work has shaped current practice. Richard Champlin, MD, at MD Anderson Cancer Center, published the foundational donor leukocyte infusion study (1,257 citations), developed the reduced-intensity "transplant-lite" approach (927 citations), and contributed to the non-myeloablative conditioning study that expanded eligibility to older patients (1,153 citations). William Bensinger, MD, Associate Professor of Medicine at the University of Washington at Swedish Medical Center, led the randomized trial comparing peripheral blood stem cells to bone marrow (961 citations) and contributed to foundational GVHD prophylaxis research (1,451 citations) and the reduced-intensity transplant study for older patients (1,392 citations). Martha Lacy, MD, Professor of Medicine at Mayo Clinic, published on myeloma transplant sequencing. Sally Arai, MD, Professor of Medicine at Stanford, co-authored the NIH Consensus criteria for chronic GVHD (5,287 citations) — the document that defines how GVHD is graded and managed universally. Richard Maziarz, MD, Medical Director of the Adult BMT and Cellular Therapy Program at OHSU, validated the Disease Risk Index for predicting transplant outcomes (921 citations) and published on conditioning intensity in AML with measurable residual disease (435 citations).

What is allogeneic stem cell transplant?

In an allogeneic transplant, stem cells come from a donor rather than the patient. The process involves:

1. Conditioning: The patient receives high-dose chemotherapy, with or without radiation, to destroy the diseased marrow and suppress the immune system sufficiently to prevent rejection
2. Infusion: The donor's stem cells (either from bone marrow or peripheral blood, after mobilization with growth factor) are infused intravenously, like a blood transfusion
3. Engraftment: The donor cells migrate to the patient's marrow cavities and begin producing new blood cells — typically 2–4 weeks after infusion
4. Immune reconstitution: Over months to years, the donor immune system gradually replaces the patient's immune system

The key biological mechanism beyond simple marrow replacement is the graft-versus-leukemia (GVL) effect: donor immune cells recognize the patient's residual cancer cells as foreign and attack them. This is why allogeneic transplant can cure cancers that autologous (patient's own cells) transplant cannot — the donor immune system provides ongoing cancer surveillance.

Donor sources

HLA-matched sibling: The preferred donor when available. Full HLA matching at the critical loci (HLA-A, B, C, DRB1) minimizes GVHD risk. Approximately 25–30% of patients have a matched sibling.

Matched unrelated donor (MUD): Found through the National Marrow Donor Program registry. A 2004 study published in the New England Journal of Medicine that Dr. Champlin contributed to (1,056 citations) compared outcomes after cord blood versus bone marrow from unrelated donors in adults with leukemia and found that well-matched unrelated donor bone marrow produced outcomes comparable to matched sibling transplants, validating MUD transplant as a standard approach.

Peripheral blood stem cells vs. bone marrow: Dr. Bensinger led the randomized FHCRC trial comparing peripheral blood (mobilized with G-CSF) to bone marrow from HLA-identical siblings (961 citations). Peripheral blood engrafted faster (median 16 vs. 21 days to neutrophil recovery) and produced similar rates of GVHD and overall survival, with more rapid immune recovery making peripheral blood the preferred donor source for many centers.

Haploidentical donors: A parent, child, or sibling who shares only half of the patient's HLA type — post-transplant cyclophosphamide protocols have made haploidentical transplants feasible, greatly expanding donor availability for patients lacking matched siblings or MUDs.

Cord blood: Publicly banked umbilical cord blood units offer rapid availability and greater tolerance for HLA mismatch but limited cell dose. The NEJM study cited above showed cord blood outcomes were inferior to well-matched unrelated donor marrow in adults, limiting its use to patients who lack other donor options or who need urgent transplant.

Myeloablative vs. reduced-intensity conditioning

The original allogeneic transplant approach used myeloablative conditioning (MAC) — high-dose cyclophosphamide plus total body irradiation or busulfan — designed to eliminate all residual leukemia cells with maximum intensity. This approach is highly effective but carries significant treatment-related mortality, historically 15–25% in the first 100 days, due to infections, organ damage, and GVHD. MAC was largely restricted to patients under 55–60.

Dr. Champlin's 1997 work in Blood (1,153 citations) demonstrated that engraftment of allogeneic cells could be achieved with fludarabine-based non-myeloablative conditioning, harnessing the GVL effect without destroying the marrow. His 1998 "transplant-lite" paper (927 citations) showed that fludarabine-based nonablative conditioning produced meaningful disease responses in lymphoid malignancies through donor immune-mediated tumor killing rather than chemotherapy-induced tumor kill.

Dr. Bensinger and colleagues published a study in Blood in 2001 (1,392 citations) of 45 patients with a median age of 56 who received reduced-intensity conditioning (200 cGy total body irradiation) with post-transplant mycophenolate and cyclosporine. The approach was feasible and produced disease responses — opening transplant to patients over 60 who were previously excluded. Today, reduced-intensity conditioning (RIC) transplants are routine at major centers for patients in their 60s and 70s with adequate organ function.

The Disease Risk Index

Not all patients benefit equally from transplant. Dr. Maziarz contributed to the validation and refinement of the Disease Risk Index (DRI), published in Blood in 2014 (921 citations), which classifies patients into low, intermediate, high, and very high risk based on their disease type and stage. The DRI predicts 4-year overall survival ranging from approximately 64% (low DRI) to 18% (very high DRI) after transplant. This index helps physicians counsel patients about realistic expectations and informs decisions about whether to proceed to transplant versus other approaches.

Graft-versus-host disease

GVHD is the major complication of allogeneic transplant and arises when donor T cells recognize the patient's tissues as foreign and attack them. Acute GVHD typically occurs within the first 100 days and primarily affects the skin, gastrointestinal tract, and liver. Prevention with methotrexate plus cyclosporine — established by the landmark 1986 trial that Dr. Bensinger contributed to (1,451 citations) — became standard of care.

Chronic GVHD occurs after day 100 and can affect virtually any organ, resembling autoimmune disease. Dr. Arai co-authored the 2014 NIH Consensus criteria for chronic GVHD (5,287 citations), which standardized how chronic GVHD is diagnosed, graded (mild, moderate, severe), and monitored. These criteria are now used universally in clinical practice and trials. Chronic GVHD affects approximately 30–70% of long-term transplant survivors and ranges from mild and manageable to severe and disabling.

Dr. Champlin's donor leukocyte infusion (DLI) study (1,257 citations) showed that infusing additional donor T cells into patients who relapse after transplant can produce remissions through the GVL effect — demonstrating that the immune mechanism is real and can be reinforced after the initial transplant.

Questions to ask your doctor

• At what disease stage (first remission? second remission?) should I be evaluated for transplant, and does timing affect outcomes?
• Do I have a matched sibling donor, and if not, how long does it typically take to find a matched unrelated donor through the registry?
• Based on my age, health status, and disease risk, would myeloablative or reduced-intensity conditioning be more appropriate?
• What is my Disease Risk Index score, and what does it predict about my likely outcome after transplant?
• How will graft-versus-host disease be prevented, and what is the plan if I develop it?
• If I relapse after transplant, is donor leukocyte infusion or a second transplant a viable option?

The bottom line

Allogeneic stem cell transplant is the only potentially curative treatment for many high-risk blood cancers, offering cure rates of 40–60% for appropriately selected patients. Reduced-intensity conditioning has extended eligibility to patients in their 60s and 70s, significantly broadening access. The critical risks — particularly graft-versus-host disease and treatment-related mortality — require careful patient selection and experienced transplant center management. Evaluating transplant candidacy early in the disease course, before relapse or progression, generally produces better outcomes.